The clinical efficacy of anlotinib-targeted therapy combined with chemotherapy for the treatment of advanced breast cancer
Objective To analyze the clinical effect of anlotinib-targeted therapy combined with chemotherapy for the treatment of advanced breast cancer. Methods 76 patients with advanced breast cancer were selected and divided into an observation group and a control group according to random numerical table method,each consisting of 38 patients. The control group received chemotherapy,and the observation group used anlotinib-targeted therapy combined with chemotherapy. The short-term efficacy,incidence of adverse reactions during treatment,and physical health scores of the two groups were compared. Results Before treatment,there was no significant difference in Karnofsky performance status scale (KPS) score between the observation group and the control group (P>0.05). After treatment,KPS score of (87.63±9.86) points in the observation group was higher than (76.84±8.35) points in the control group,and the difference between groups was statistically significant (t=5.148,P<0.05). The objective response rate (ORR) of 68.42％ in the observation group was higher than 44.74％ in the control group,and the difference between groups was statistically significant (x2=4.338,P<0.05). The incidence of hypertension (36.84％),abnormal liver function (52.63％) and dyslipidemia (42.11％) in the observation group were lower than 15.79％,26.32％ and 21.05％ in the control group,and the differences between groups were statistically significant (x2=4.343,5.507,3.897;P<0.05). There were no significant differences in the incidence of myelosuppression and proteinuria between the two groups (P>0.05). Conclusion Anlotinib-targeted therapy combined with chemotherapy shows better effect for advanced breast cancer,which can improve the tumor control rate and improve the health status of patients.
Advanced breast cancerAnlotinibTargeted therapyChemotherapyClinical efficacy
万方数据
维普
